Steven Yatomi-Clarke, CEO & MD of Prescient Therapeutics (ASX:PTX) provides an update on the company’s three new next-gen CAR-T programs and using OmniCAR’s unique features to create therapies where current generation CAR-Ts have struggled,  which inserts PTX into the forefront of global CAR-T research

Recorded on 21 January 2021 at 1pm (AEDT)

Join the next Prescient Therapeutics webcast